Table 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors

Key Points

• Basroparib demonstrated safety and potential efficacy in patients with advanced-stage solid tumors, indicating further investigation is warranted.
• This phase I trial included 25 patients, revealing promising activity against advanced cancers treated with basroparib.
• The dose-escalation study design aims to identify the safest and most effective dosage for future research on tankyrase inhibitors.
• Outcomes highlight the need for follow-up studies to validate the role of tankyrase inhibitors in treating solid tumors.